CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

Summary: Response determinants to immunotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC) remain unclear, limiting treatment advancements. We report a single-arm phase 1b/2 study (OPTIMIZE-1) evaluating the safety and efficacy of the cluster of differentiation 40 (CD40) agonist mitazali...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, Teresa Macarulla Mercade, Aurélien Lambert, Philippe Cassier, Hans Prenen, Emmanuel Mitry, Jean-Frédéric Blanc, Lorenzo Pilla, Jaime Feliu, Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid, Inmaculada Gallego, Karin Enell Smith, Karin Nordbladh, David Gomez Jimenez, Peter Ellmark, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Gregory L. Beatty, Eileen M. O'Reilly
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-10-01
Colecção:	Cell Reports Medicine
Assuntos:	CD40 agonist mitazalimab mPDAC biomarker immunotherapy chemotherapy
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S266637912500480X
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!